L.E.M laboratory provides breast cancer genomic classification using Prosigna, call now and order a high quality professional state of the art test for your patients- Phone : 08-9380770.
From Nanostring Technologies news general releases, Dec, 2016:
"Prosigna Breast Cancer Assay Outperforms All Other Commercial Assays Tested in Updated Analysis of TransATAC Study Presented at the 39th Annual CTRC-AACR San Antonio Breast Cancer Symposium.
Prosigna Provides the Most Prognostic Information of Four Genomic Tests in Head-to-Head Comparison of Early Breast Cancer Node-Negative Patients Over a 10-Year Period.
SEATTLE, Dec. 12, 2016 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today highlighted study findings relating to the prognostic value of the PAM50-based Prosigna® Breast Cancer Gene Signature Assay in treating breast cancer that were presented at the 2016 CTRC-AACR San Antonio Breast Cancer Symposium (SABCS). Investigators retrospectively evaluated and compared the performance of four multigene expression profiles to predict the risk of Distant Recurrence (DR) in the same large dataset of more than 800 patients from the TransATAC study. These signatures included Prosigna, Oncotype DX®, EndoPredict® and Breast Cancer IndexSM.
For post-menopausal women with node-negative, hormone receptor-positive, HER2-negative early stage breast cancer, the study found that Prosigna provided the most accurate prognostic information of all four multigene expression profiles tested as measured by the statistical measure known as the likelihood ratio. The study further found that Prosigna also provided the most accurate differentiation between low and high risk patients as compared to the other genomic tests. Low-risk women as identified by Prosigna had a 3% risk of DR over 10 years, the lowest rates of DR for all genomic tests that were studied. In contrast, high-risk women as identified by Prosigna had on average a 33% chance of distant recurrence by 10 years.
These results support the conclusions of the 2016 evidence-based ASCO guidelines that multi-gene expression signatures provide clinical utility for selection of low risk patients who may be spared adjuvant chemotherapy based upon their outcomes when treated with hormone therapy alone. Those guidelines gave a strong recommendation for Prosigna, equivalent to the recommendation given for Oncotype Dx and stronger than other tests evaluated by the guideline committee..."